Skip to main content

Latanoprost (Monograph)

Brand names: Xalatan, Xelpros
Drug class: Prostaglandin Analogs
VA class: OP109
Molecular formula: C26H40O5
CAS number: 130209-82-4

Medically reviewed by Drugs.com on Oct 9, 2023. Written by ASHP.

Introduction

Ocular hypotensive agent; a synthetic analog of prostaglandin F2α (PGF2α).1 2 3 32 33

Uses for Latanoprost

Ocular Hypertension and Glaucoma

Latanoprost 0.005%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.1 3 10 11 12 13 15 30 31 32 33 48 55 60 90 91

Appears to be more effective than unoprostone (not available in US), as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.76 77 78 79 80 81

May be more effective or at least as effective as twice-daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension.1 3 10 11 12 30 31 32 33 Appears to be more effective than thrice-daily administration of dorzolamide 2%.86 87

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.1 3 10 11 12 15 36 44 48

Fixed-combination netarsudil 0.02% and latanoprost 0.005%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.91 When administered once daily, mean IOP reduction was approximately 1–3 mm Hg greater than that achieved with once-daily administration of either drug alone.91 92

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost).130 132 With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.130 131

A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activity, once-daily administration, and low frequency of systemic adverse effects; however, ocular adverse effects can occur.130 131 132 134

Goal is to maintain an IOP at which visual field loss is unlikely to substantially reduce quality of life during the patient's lifetime.130 132

Reduction of pretreatment IOP by ≥25% shown to slow progression of primary open-angle glaucoma.130 131 Set an initial target IOP (based on extent of optic nerve damage and/or visual field loss, baseline IOP at which damage occurred, rate of progression, life expectancy, and other considerations) and reduce IOP toward this goal.130 131 132 Adjust target IOP up or down as needed over course of disease.130 131 132

Combination therapy with drugs from different therapeutic classes often required to control IOP.131 133

Latanoprost Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the affected eye(s) as an ophthalmic emulsion (latanoprost) or ophthalmic solution (latanoprost alone or in fixed combination with netarsudil).1 10 11 12 32 33 36 90 91

Avoid contamination of the dispensing container.1 90 91 (See Bacterial Keratitis under Cautions.)

Remove contact lenses before administering each dose; may reinsert lenses 15 minutes after the dose.1 90 91

If more than one topical ophthalmic preparation is used, administer the preparations at least 5 minutes apart.1 90 91

Dosage

Adults

Ocular Hypertension and Glaucoma
Ophthalmic

Latanoprost 0.005% ophthalmic solution or emulsion: One drop in the affected eye(s) once daily in the evening.1 10 11 12 32 33 36 90

Netarsudil 0.02% and latanoprost 0.005% ophthalmic solution: One drop in the affected eye(s) once daily in the evening.91

More frequent dosing may diminish the IOP-lowering effect of latanoprost or cause paradoxical elevation of IOP.1 15 29 39 90 91

If target IOP not achieved, may initiate additional or alternative ocular hypotensive agents.130 131 133 (See Ocular Hypertension and Glaucoma under Uses.) However, concomitant use of ≥2 prostaglandin analogs not recommended.1 90

If a dose is missed, continue the usual schedule with the next dose applied the following evening.1 15 90 91

Special Populations

No special population dosage recommendations at this time.1 90 91

Detailed Latanoprost ophthalmic dosage information

Cautions for Latanoprost

Contraindications

Warnings/Precautions

Pigmentation

Increased pigmentation of the iris and periorbital tissue (eyelid) reported.1 3 10 11 12 15 31 32 33 36 Pigmentation expected to increase as long as latanoprost is administered.1 Following discontinuance of therapy, pigmentation of the iris is likely to be permanent, while pigmentation of periorbital tissue reportedly is reversible in some patients.1 Long-term effects (i.e., beyond 5 years) of increased pigmentation are unknown.1

Increased pigmentation of iris may not be evident until after several months to years of latanoprost therapy.1 May continue therapy in patients who develop noticeably increased iris pigmentation;1 however, examine these patients regularly.1 33 36

Eyelash Changes

Possible gradual change in eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, and number of eyelashes and/or misdirected growth of eyelashes.1 3 10 11 12 15 31 32 33 36 Usually reversible upon discontinuance of therapy.1

Intraocular Inflammation

Use with caution in patients with a history of intraocular inflammation (e.g., iritis, uveitis); use generally not recommended in patients with active intraocular inflammation since latanoprost may exacerbate inflammation.1

Macular Edema

Macular edema, including cystoid macular edema, reported in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema; use with caution in such patients.1 51 52 53 54 58 61 62 63 64 65

Herpetic Keratitis

Reactivation of herpes simplex keratitis reported.1 Use with caution in patients with a history of herpetic keratitis; avoid use in those with active herpes simplex keratitis since latanoprost may exacerbate inflammation.1

Bacterial Keratitis

Bacterial keratitis reported with use of multiple-dose containers of topical ophthalmic preparations.1 Containers were inadvertently contaminated by patients, most of whom had concurrent corneal disease or disruption of the ocular epithelial surface.1

Improper handling of ophthalmic solutions can result in contamination of the solution by common bacteria known to cause ocular infections.1 Serious damage to the eye and subsequent loss of vision may result from using contaminated ophthalmic solutions.1 (See Advice to Patients.)

Use with Contact Lenses

Remove contact lenses before administering each dose; may reinsert lenses 15 minutes after the dose.1 90 91

Use of Fixed Combinations

When used in fixed combination with netarsudil, consider the cautions, precautions, and contraindications associated with netarsudil.91

Specific Populations

Pregnancy

Category C.1 90

Use only if potential benefits justify possible risks to the fetus.1 90 91

Lactation

Not known whether latanoprost distributes into milk,1 90 91 affects the breast-fed infant, or affects milk production.91

Latanoprost ophthalmic solution or emulsion: Use with caution.1 90

Netarsudil and latanoprost fixed-combination ophthalmic solution: Consider developmental and health benefits of breast-feeding along with the mother's clinical need for the drugs and any potential adverse effects of the drugs on the breast-fed infant.91

Pediatric Use

Safety and efficacy not established in pediatric patients.1 15 90 91

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.1 10 11 12 90 91

Common Adverse Effects

Latanoprost ophthalmic solution: Foreign body sensation, punctate keratitis, ocular stinging, conjunctival hyperemia, blurred vision, ocular pruritus, ocular burning, increased pigmentation of the iris.1

Latanoprost ophthalmic emulsion: Eye pain/stinging upon instillation, ocular hyperemia, conjunctival hyperemia, eye discharge, eyelash growth or thickening, ocular pruritus.90

Netarsudil and latanoprost ophthalmic solution: Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage, ocular pruritus, decreased visual acuity, increased lacrimation, instillation site discomfort, blurred vision.91

Drug Interactions

Specific Drugs

Drug

Interaction

Comments

Thimerosal

Ophthalmic preparations containing thimerosal: Precipitation occurs when admixed with latanoprost ophthalmic solution or emulsion1 90 91

Administer latanoprost and thimerosal-containing preparations ≥5 minutes apart1
Latanoprost ophthalmic drug interactions (more detail)

Latanoprost Pharmacokinetics

Absorption

Bioavailability

Approximately 1% of a topically applied dose penetrates the human eye;15 remaining portion is absorbed into systemic circulation through blood vessels in the conjunctiva and mucous membranes of the nose, pharynx, esophagus, and GI tract.6 15

Prodrug; absorbed through the cornea following ocular instillation and rapidly hydrolyzed to active form (latanoprost acid).1 6 14 15 16 18 Peak aqueous humor concentrations of latanoprost acid occur within 2 hours.1 15

Onset

Reduction in IOP generally occurs within 3–4 hours after topical application and peaks within 8–12 hours.

Duration

Effects on IOP generally persist for up to 24 hours or longer.1 10 11 12 13 15 17

Following long-term therapy (i.e., 6 months), pharmacologic effects may persist for at least 14 days after the drug is discontinued.15

Distribution

Extent

The volume of distribution of latanoprost acid in humans following ocular or IV administration is 0.36 or 0.16 L/kg, respectively.1 15 Latanoprost acid can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after ocular instillation.1

Not known whether the drug or its metabolites distribute into milk in humans.1

Elimination

Metabolism

Rapidly hydrolyzed by esterases in the cornea and plasma to biologically active form (latanoprost acid).1 15 16 33

Systemically absorbed latanoprost acid is metabolized in the liver.1 15

Elimination Route

Metabolites are excreted principally in urine; however, biliary excretion also may occur.1 6 15 Unchanged latanoprost or latanoprost acid generally are not recovered in urine or feces.15 Following topical administration of radiolabeled latanoprost to the eye, 88% of the dose was eliminated in urine.15

Half-life

The elimination half-life of latanoprost acid from aqueous humor is approximately 3 hours.15

Following topical application to the eye, the plasma elimination half-life of latanoprost acid is approximately 17 minutes.15

Stability

Storage

Ophthalmic

Emulsion

Latanoprost: Store at 2–25°C and protect from light; may use opened bottle until the manufacturer's labeled expiration date.90 During shipping, may be maintained at up to 40°C for ≤8 days.90

Solution

Latanoprost: Store unopened bottle at 2–8°C and protect from light.1 15 During shipping, may be maintained at up to 40°C for ≤8 days.1 May store opened bottle at room temperature for ≤6 weeks; do not expose opened bottle to temperatures >25°C.1

Netarsudil and latanoprost: Store at 2–8°C and protect from light; may use opened bottle until the manufacturer's labeled expiration date.91 During shipping, may be maintained at up to 40°C for ≤14 days.91

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Latanoprost

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Emulsion

0.005%

Xelpros

Sun

Solution

0.005%*

Latanoprost Ophthalmic Solution

Xalatan

Pfizer
Latanoprost Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Solution

0.005% with Netarsudil Mesylate 0.02% (of netarsudil)

Rocklatan

Aerie

AHFS DI Essentials™. © Copyright 2024, Selected Revisions October 19, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Pfizer. Xalatan (latanoprost) ophthalmic solution 0.005% prescribing information. New York, NY; 2017 Apr.

2. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 1992; 17:691-704.

3. Camras CB. Prostaglandins. In: Ritch R, Shields MB, Krupin T eds. The glaucomas. 2nd ed. St. Louis: Mosby-Year Book, Inc; 1996:1449-61.

4. Campbell WB, Halushka PV. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Hardman JG, Limbird LE, Molinoff PB et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:601-16.

5. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993; 100:1297-304. http://www.ncbi.nlm.nih.gov/pubmed/8371915?dopt=AbstractPlus

6. Stjernschantz J, Selén G, Sjöquist B et al. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2α analogue. Adv Prostaglandin Thromboxane Leukotriene Res. 1995; 23:513-8.

7. True Gabelt B, Kaufman PL. Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989; 49:389-402. http://www.ncbi.nlm.nih.gov/pubmed/2792235?dopt=AbstractPlus

8. Nilsson SFE, Samuelsson M, Bill A et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989; 48:707-16. http://www.ncbi.nlm.nih.gov/pubmed/2737263?dopt=AbstractPlus

9. Ziai N, Dolan JW, Kacere RD et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993; 111:1351-8. http://www.ncbi.nlm.nih.gov/pubmed/8216015?dopt=AbstractPlus

10. Alm A, Stjernschantz J, and the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995; 102:1743-52. http://www.ncbi.nlm.nih.gov/pubmed/9098273?dopt=AbstractPlus

11. Camras CB, and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996; 103:138-47. http://www.ncbi.nlm.nih.gov/pubmed/8628544?dopt=AbstractPlus

12. Watson P, Stjernschantz J, and the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996; 103:126-37. http://www.ncbi.nlm.nih.gov/pubmed/8628543?dopt=AbstractPlus

13. Rácz P, Ruzsonyi MR, Nagy ZT et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996; 114:268-73. http://www.ncbi.nlm.nih.gov/pubmed/8600885?dopt=AbstractPlus

14. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2α, PGF2α-1-methyl ester, and PGF2α-1-isopropyl ester. Exp Eye Res. 1987; 44:217-26. http://www.ncbi.nlm.nih.gov/pubmed/3472899?dopt=AbstractPlus

15. Pharmacia & Upjohn Inc, Kalamazoo, MI: Personal communication.

16. Basu S, Sjöquist B, Stjernschantz J et al. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukotrienes Essent Fatty Acids. 1994; 50:161-8.

17. Rácz P, Ruzsonyi MR, Nagy ZT et al. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2α analogue (PhXA41): an in-hospital, placebo-controlled study. Arch Ophthalmol. 1993; 111:657-61. http://www.ncbi.nlm.nih.gov/pubmed/8489449?dopt=AbstractPlus

18. Bito LZ, Stjernschantz J, Resul B et al. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2α analog, PhXA41 (latanoprost), for glaucoma management. J Lipid Mediators. 1993; 6:535-43.

19. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993; 111:662-5. http://www.ncbi.nlm.nih.gov/pubmed/8489450?dopt=AbstractPlus

20. Alm A, Villumsen J, Törnquist P et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study. Ophthalmology. 1993; 100:1312-7. http://www.ncbi.nlm.nih.gov/pubmed/8371917?dopt=AbstractPlus

21. Lichter PR. Another blockbuster glaucoma drug? Ophthalmology. 1993; 100:1281-2. Editorial.

22. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging. 1994; 5:156-70. http://www.ncbi.nlm.nih.gov/pubmed/7803944?dopt=AbstractPlus

23. Bienfang DC, Kelly LD, Nicholson DH et al. Ophthalmology. N Engl J Med. 1990; 323:956-67. http://www.ncbi.nlm.nih.gov/pubmed/2205800?dopt=AbstractPlus

24. Cotton P. Glaucoma: detection before damage, fewer side effects may be possible. JAMA. 1990; 264:1793. http://www.ncbi.nlm.nih.gov/pubmed/2402030?dopt=AbstractPlus

25. Rosenberg LF. Glaucoma: early detection and therapy for prevention of vision loss. Am Fam Physician. 1995; 52:2289-98. http://www.ncbi.nlm.nih.gov/pubmed/7484722?dopt=AbstractPlus

26. Chaudhry I, Wong S. Recognizing glaucoma. A guide for the primary care physician. Postgrad Med. 1996; 99:247-8,251-2,257-9.

27. Hayreh SS, Zimmerman MB, Podhajsky P et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994; 117: 603-24.

28. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994; 78:899-902. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=504988&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7819171?dopt=AbstractPlus

29. Alm A, Widengard I, Kjellgren D et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995; 79:12-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=505011&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7880782?dopt=AbstractPlus

30. Mishima HK, Masuda K, Kitazawa Y et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. Arch Ophthalmol. 1996; 114: 929-932. http://www.ncbi.nlm.nih.gov/pubmed/8694726?dopt=AbstractPlus

31. Higginbotham EJ. Will latanoprost be the “wonder” drug of the ’90s for the treatment of glaucoma? Arch Ophthalmol. 1996; 114:998-999.

32. Anon. A topical prostaglandin for glaucoma. Med Lett Drugs Ther. 1996; 38:100-1. http://www.ncbi.nlm.nih.gov/pubmed/8914508?dopt=AbstractPlus

33. Patel SS, Spencer CM. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996; 9:363-78. http://www.ncbi.nlm.nih.gov/pubmed/8922563?dopt=AbstractPlus

34. The eye: I. Optics of vision. In: Guyton AC ed. Textbook of medical physiology. 8th ed. Philadelphia: WB Saunders Company; 1991:542-4.

35. Prostaglandin. Dorland’s illustrated medical dictionary. 28th ed. Philadelphia: WB Saunders Company; 1994:1366.

36. Camras CB, Alm A, Watson P et al et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Ophthalmology. 1996; 103:1916-24. http://www.ncbi.nlm.nih.gov/pubmed/8942890?dopt=AbstractPlus

37. Rulo AH, Greve EL, Geijssen HC et al. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996; 103:1276-82. http://www.ncbi.nlm.nih.gov/pubmed/8764799?dopt=AbstractPlus

38. Nicolela MT, Buckley AR, Walman BE et al. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol. 1996; 122:784-9. http://www.ncbi.nlm.nih.gov/pubmed/8956632?dopt=AbstractPlus

39. Nagasubramanian S, Sheth GP, Hitchings RA et al. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology. 1993; 100:1305-11. http://www.ncbi.nlm.nih.gov/pubmed/8371916?dopt=AbstractPlus

40. Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994; 46:205-29. http://www.ncbi.nlm.nih.gov/pubmed/7938166?dopt=AbstractPlus

41. Johnstone MA. Hypertrichosis and increased pigmentation of lashes and adjacent hair in the region of the eye in patients treated with unilateral topical latanoprost. Am J Ophthalmol. (in press)

42. Lindsey JD, Kashiwagi K, Boyle D et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996; 15: 869-75.

43. Lindsey JD, Kashiwagi K, Kashiwagi F et al. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol. 1997; 42(Suppl 2):S53-9.

44. Reviewers’ comments (personal observations).

46. Alward WLM. Medical management of glaucoma. N Engl J Med. 1998; 339:1298-307. http://www.ncbi.nlm.nih.gov/pubmed/9791148?dopt=AbstractPlus

47. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987; 105:1112-6. http://www.ncbi.nlm.nih.gov/pubmed/3477218?dopt=AbstractPlus

48. Watson PG, and the Latanoprost Study Group. Latanoprost: two years’ experience of its use in the United Kingdom. Ophthalmology. 1998; 105:82-7. http://www.ncbi.nlm.nih.gov/pubmed/9442782?dopt=AbstractPlus

49. Peak AS, Sutton BM. Systmic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998; 32:504-5. http://www.ncbi.nlm.nih.gov/pubmed/9562149?dopt=AbstractPlus

50. Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with latanoprost. Eye. 1998; 12:741-3. http://www.ncbi.nlm.nih.gov/pubmed/9850277?dopt=AbstractPlus

51. Ayyala RS, Cruz DA, Margo CE et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998; 126:602-4. http://www.ncbi.nlm.nih.gov/pubmed/9780112?dopt=AbstractPlus

52. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998; 105:1981-3. http://www.ncbi.nlm.nih.gov/pubmed/9818590?dopt=AbstractPlus

53. Camras CB. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998; 105:1978-81. http://www.ncbi.nlm.nih.gov/pubmed/9818589?dopt=AbstractPlus

54. Eisenberg D. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998; 105:1978. http://www.ncbi.nlm.nih.gov/pubmed/9818588?dopt=AbstractPlus

55. Camras CB, Wax MB, Ritch R et al and the United States Latanoprost Study Group. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol. 1998; 126:390-9. http://www.ncbi.nlm.nih.gov/pubmed/9744372?dopt=AbstractPlus

56. Vanlandigham BD, Brubaker RF. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am J Ophthalmol. 1998; 126:191-6. http://www.ncbi.nlm.nih.gov/pubmed/9727512?dopt=AbstractPlus

57. Fechtner RD, Khouri AS, Zimmerman TJ et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126:37-41. http://www.ncbi.nlm.nih.gov/pubmed/9683147?dopt=AbstractPlus

58. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998; 126:134-5. http://www.ncbi.nlm.nih.gov/pubmed/9683162?dopt=AbstractPlus

59. Widengard I, Maepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol. 1998; 82:404-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1722565&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9640189?dopt=AbstractPlus

60. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998; 125:585-92. http://www.ncbi.nlm.nih.gov/pubmed/9625541?dopt=AbstractPlus

61. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998; 116:680-2. http://www.ncbi.nlm.nih.gov/pubmed/9596510?dopt=AbstractPlus

62. Avakian A, Renier SA, Butler PJ. Adverse effects of latanaprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998; 116:679-80. http://www.ncbi.nlm.nih.gov/pubmed/9596509?dopt=AbstractPlus

63. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc. 1998; 69:122-8. http://www.ncbi.nlm.nih.gov/pubmed/9549261?dopt=AbstractPlus

64. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998; 105:263-8. http://www.ncbi.nlm.nih.gov/pubmed/9479285?dopt=AbstractPlus

65. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997; 124:683-5. http://www.ncbi.nlm.nih.gov/pubmed/9372723?dopt=AbstractPlus

66. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997; 115:1206-8. http://www.ncbi.nlm.nih.gov/pubmed/9298071?dopt=AbstractPlus

67. Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol. 1999; 117:1305-9. http://www.ncbi.nlm.nih.gov/pubmed/10532438?dopt=AbstractPlus

68. Kent AR, Vroman DT, Thomas TJ et al. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma. 1999; 8:257-62. http://www.ncbi.nlm.nih.gov/pubmed/10464735?dopt=AbstractPlus

69. Moroi SE, Gottfredsdottir MS, Schteingart MT et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999; 106:1024-9. http://www.ncbi.nlm.nih.gov/pubmed/10328408?dopt=AbstractPlus

70. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999; 127:602-4. http://www.ncbi.nlm.nih.gov/pubmed/10334356?dopt=AbstractPlus

71. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001; 119:300-1. http://www.ncbi.nlm.nih.gov/pubmed/11176999?dopt=AbstractPlus

72. Wand M, Ritch R, Isbey EK et al. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001; 119:614-5. http://www.ncbi.nlm.nih.gov/pubmed/11296032?dopt=AbstractPlus

73. Demitsu T, Manabe M, Harima N et al. Hypertrichosis induced by latanoprost. J Am Acad Dermatol. 2001; 44:721-3. http://www.ncbi.nlm.nih.gov/pubmed/11260563?dopt=AbstractPlus

74. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002; 47(suppl 1):S185-202.

75. Distelhorst JS and Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003; 67: 1937-44. http://www.ncbi.nlm.nih.gov/pubmed/12751655?dopt=AbstractPlus

76. Noecker RS, Dirks MS, Choplin NT et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135:55-63. http://www.ncbi.nlm.nih.gov/pubmed/12504698?dopt=AbstractPlus

77. Choplin N, Bernstein P, Batoosingh AL et al. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004; 49(suppl 1):S19-25. http://www.ncbi.nlm.nih.gov/pubmed/15016558?dopt=AbstractPlus

78. Gandolfi S, Simmons ST, Sturm R et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18:110-21. http://www.ncbi.nlm.nih.gov/pubmed/11571823?dopt=AbstractPlus

79. Dubiner H, Cooke D, Dirks M et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45(suppl 4):S353-60. http://www.ncbi.nlm.nih.gov/pubmed/11434938?dopt=AbstractPlus

80. Dubiner HB, Sircy MD, Landry T et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004; 26:84-91. http://www.ncbi.nlm.nih.gov/pubmed/14996520?dopt=AbstractPlus

81. Perry CM, McGavin JK,, Culy CR et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging. 2003; 20:597-630. http://www.ncbi.nlm.nih.gov/pubmed/12795627?dopt=AbstractPlus

82. Jampel HD, Bacharach J, Sheu WP et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002; 134:863-71. http://www.ncbi.nlm.nih.gov/pubmed/12470755?dopt=AbstractPlus

83. Sponsel WE, Paris G, Trigo Y et al. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol. 2002; 134:552-9. http://www.ncbi.nlm.nih.gov/pubmed/12383812?dopt=AbstractPlus

84. Aung T, Chew PT, Yip CC et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001; 131:636-42. http://www.ncbi.nlm.nih.gov/pubmed/11336940?dopt=AbstractPlus

85. Susanna R Jr, Giampani J Jr, Borges AS et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001; 108:259-63. http://www.ncbi.nlm.nih.gov/pubmed/11158796?dopt=AbstractPlus

86. Niazi MK and Raja N. Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma. J Ayub Med Coll Abbottabad. 2004; 16:50-3. http://www.ncbi.nlm.nih.gov/pubmed/15125183?dopt=AbstractPlus

87. O’Donoghue EP for the Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol. 2000; 84:579-82. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1723499&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10837379?dopt=AbstractPlus

88. Shin DH, McCracken MS, Bendel RE et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology. 1999; 106:386-90. http://www.ncbi.nlm.nih.gov/pubmed/9951495?dopt=AbstractPlus

89. Toris CB, Zhan GL, Zhao J et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001; 131:722-8. http://www.ncbi.nlm.nih.gov/pubmed/11384567?dopt=AbstractPlus

90. Sun Pharmaceutical Industries. Xelpros (latanoprost) ophthalmic emulsion 0.005% prescribing information. Cranbury, NJ; 2018 Sep.

91. Aerie Pharmaceuticals. Rocklatan (netarsudil and latanoprost) ophthalmic solution 0.02%/0.005% prescribing information. Irvine, CA; 2019 Mar.

92. Asrani S, Robin AL, Serle JB et al. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial. Am J Ophthalmol. 2019; http://www.ncbi.nlm.nih.gov/pubmed/31229466?dopt=AbstractPlus

130. Prum BE Jr, Rosenberg LF, Gedde SJ et al. Primary open-angle glaucoma preferred practice pattern guideline [published corrigendum appears in Ophthalmology. 2018; 125: 949]. San Francisco, CA: American Academy of Ophthalmology; 2015. From the American Academy of Ophthalmology website. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp-2015

131. Liebmann JM, Lee JK. Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. Am J Manag Care. 2017; 23(15 Suppl):S279-S292. http://www.ncbi.nlm.nih.gov/pubmed/29164845?dopt=AbstractPlus

132. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311:1901-11. http://www.ncbi.nlm.nih.gov/pubmed/24825645?dopt=AbstractPlus

133. Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016; 93:668-74. http://www.ncbi.nlm.nih.gov/pubmed/27175839?dopt=AbstractPlus

134. Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014; 8:903-13. http://www.ncbi.nlm.nih.gov/pubmed/24872675?dopt=AbstractPlus

Frequently asked questions

Medical Disclaimer